The Ubiquitin Proteasome System as a Therapeutic Area in Parkinson’s Disease
Progenra Inc, February 2023 Parkinson’s disease (PD) is the most common neurodegenerative movement disorder. There are no available therapeutics that slow or halt the progressive loss of dopamine-producing neurons, which underlies the primary clinical symptoms. Currently approved PD drugs can provide symptomatic relief by increasing brain dopamine content or activity; however, the alleviation is temporary, […]
Progenra receives funding from the Michael J Fox Foundation to develop Parkin activators to treat Parkinson’s disease.
May 2020. Progenra has received new funding for its Michael J. Fox Foundation Therapeutic Pipeline Award, Discovery and Development of Novel Parkin Activators. Progenra’s novel Parkin activator molecules are undergoing preclinical development, and this funding will support chemical optimization and other early preclinical activities necessary to advance the program to clinical trial for treatment of […]
Progenra Scientists publish a chapter in the ACS 2019 Medicinal Chemistry Reviews.
February 2020. Ubiquitin-specific proteases (USPs), the major class of deubiquitinating enzymes, or DUBs, remove conjugated ubiquitin from proteins in cells and in so doing help to regulate the content, location, or activity of the target protein. Approximately 80 USPs are expressed in humans, and many are linked genetically and biochemically with various diseases including cancer, […]
Characterization of Selective Covalent inhibitors of USP7- AACR Poster
Abstract- The ubiquitin-specific protease 7 (USP7) has emerged as an attractive antitumor target due to its critical roles in several cancer signaling pathways as well as its essential role in maintaining Foxp3+ T-regulatory cell (Treg) functions. Pharmacological inhibition of USP7 is therefore expected to have both direct anti-tumor activity and activity in promoting anti-tumor immunity. […]
Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs
Abstract- There are several challenges towards the development and clinical use of small molecule inhibitors, which are currently the main type of targeted therapies towards intracellular proteins. PROteolysis-TArgeting Chimeras (PROTACs) exploit the intracellular ubiquitin-proteasome systemto selectively degrade target proteins. Recently, small-molecule PROTACs with high potency have been frequently reported. In this review, we summarize the […]
Immune Regulation by Protein Ubiquitination: Roles of the E3 Ligases VHL and Itch
[et_pb_section admin_label=”section”] [et_pb_row admin_label=”row”] [et_pb_column type=”4_4″][et_pb_text admin_label=”Text”]Abstract – Protein ubiquitination is an important means of post-translational modification which plays an essential role in the regulation of various aspects of leukocyte development and function. The specificity of ubiquitin tagging to a protein substrate is determined by E3 ubiquitin ligases via defined E3-substrate interactions.In this review, we […]
Protein Misfolding-Neurodegeneration
[et_pb_section bb_built=”1″][et_pb_row][et_pb_column type=”4_4″][et_pb_text] Abstract- Mammalian cells remove misfolded proteins using various proteolytic systems, including the ubiquitin (Ub)-proteasome system (UPS), chaperone mediated autophagy (CMA) and macroautophagy. The majority of misfolded proteins are degraded by the UPS, in which Ub-conjugated substrates are deubiquitinated, unfolded and cleaved into small peptides when passing through the narrow chamber of the […]
Ubiquitination and Cancer
Abstract- Dynamic modulation and post-translational modification of proteins are tightly controlled biological processes that occur in response to physiological cues. One such dynamic modulation is ubiquitination, which marks proteins for degradation via the proteasome, altering their localization, affecting their activity, and promoting or interfering with protein interactions. Hence, ubiquitination is crucial for a plethora of […]
Hanson Wade’s Targeted Protein Degradation Conference
“Encapsulating the excitement of the field of protein degradation, the 2nd TPD Summit 2019 is the definitive comprehensive and industry-dedicated summit for the field of protein degradation – focused on optimizing target validation, improving medicinal chemistry & rational design, and ultimately accelerating the translation of selective, bioavailable and effective protein degraders into clinical trials.” Progenra […]
Cambridge Healthtech Institute’s Annual Discovery on Target Conference
CHI’s conference on PROTACs and Targeted Protein Degradation will bring together a diverse group of chemists and biologists to discuss the prospects as well as the challenges underlying strategies for targeted protein degradation. This will be preceded by a conference that discusses emerging ubiquitin and autophagy targets for therapeutic intervention. Progenra CEO Dr. Butt will […]
